"Designing Growth Strategies is in our DNA"
The global adult malignant glioma therapeutics market size was valued at USD 1,459.1 Million in 2018, is projected to reach USD 2,964.5 Million by the end of 2026, exhibiting a CAGR of 9.3%.
Gliomas are the type of tumor starting at glial cells of the brain and spine are the most common types of brain tumors. According to Atlas of Genetics and Cytogenetics in Oncology and Hematology, glioma comprises of about 30% of the brain tumors and 70% of all the malignant tumors. Glioblastoma multiforme (GBM) is the most aggressive and difficult to treat form of the disease with median survival rate of 12 months.
Growing prevalence of the disease, huge unmet need, poor survival rate, and lack of effective therapies for the complete cure of the disease leverages great opportunity for the players to invest in the research and development of glioma therapies. Currently, available therapies prescribed for adult malignant glioma therapy include surgery, chemotherapy, radiation therapy, and targeted therapies among others.
The adult malignant glioma therapeutics market share is anticipated to expand at near two digit CAGR during the forecast period attributable to supportive government and regulatory policies for the development of novel therapies, advancements in the imaging technologies resulting in early detection of the disease, and favorable reimbursement policies for the glioma products across many regions of the world.
Get comprehensive study about this report by, request a free sample copy
"Targeted therapy is expected to emerge as the most attractive treatment type"
Glioblastoma Multiforme, the most aggressive and reoccurring form of the disease is treated with first-line therapy and second-line therapy. The first line of therapies prescribed conventionally are temozolomide and radiotherapy. However, once the reoccurrence of the disease occurs, the treatment options are limited. Fortunately, advances in drug development have resulted in the successful applications of targeted therapies to improve the survival rate. Commonly used targeted therapies in the treatment of glioma are EGFR-targeted therapies, therapies targeting tyrosine kinases receptors, etc. The targeted therapy segment is projected to expand at the highest CAGR during the forecast period.
To get details on market share, speak to our analyst
In terms of disease type, the glioblastoma multiforme (GBM) held the largest adult malignant glioma therapeutic market share in the year 2018. The segment is likley to continue dominance during the forecast period. In terms of end-user, the hospital's segment accounted for a major market share. However, cancer and radiation therapy centers segment is projected to expand at the highest CAGR during the forecast period owing to the availability of medical care specific for cancer treatment
"High Prevalence of Malignant Glioma and Huge Spending on Healthcare in North America are Contributing to the Dominance of the Region in The Global Adult Malignant Glioma Therapeutics Market"
Glioblastoma multiforme is a malignant astrocytoma and the most common primary brain tumor among adults. According to the American Society of Clinical Oncology (ASCO), about 17,000 new cases of high-grade gliomas, or HGG, are expected to be diagnosed in the U.S. in 2019. Rise in the incidence of the disease, strong economy, huge spending on the healthcare, high diagnosis rate owing to awareness about the healthcare among the population are predominant factors contributing the dominance of the region in the global adult malignant glioma therapeutics market trend.
North America Adult Malignant Glioma Market, 2018
To get geographical overview of this market, request a free sample copy
"Merck & Co., Inc. and F. Hoffmann-La Roche Ltd to Account for Major Market Share in Terms of Revenue"
Temozolomide is the Merck & Co., Inc.’s leading product available in the U.S. as temodar and internationally as temodal. The company has a well-established footprint across the major markets. Moreover, its strategies to expand in the emerging economies are making the company leader in the glioma therapeutics. Roche dominates the adult malignant glioma therapeutic market with its leading product Avastin, approved for the treatment of malignant glioma due to strong clinical pieces of evidence supporting treatment merits.
Glioma is a type of tumor that arises in the glial cells of the brain or spine. These comprise of around 30-40% of the primary central nervous system tumors and about 70-80% of all the malignant brain tumors. Unmet medical needs, increase in the global prevalence of the disease, and growing affordability for advanced therapies such as targeted therapies are likely to augment the demand for products designed for the treatment of adult malignant glioma.
The glioblastoma multiforme is the most common form of the glioma occurring in the adult population. It is the deadliest form of the disease requiring high end of medical care. Despite the continuous increase in the global patient population of glioma, the incidence is still less and the products approved for the treatment comes under the orphan category. The high cost of product development and less patient population are the major factors hindering the entry of new players in the market.
The report provides qualitative and quantitative insights on adult malignant glioma therapeutics and detailed analysis of market size and growth rate for all possible segments in the market. The market is segmented by therapy, disease type, the end-user, and region. In terms of therapy, the global adult malignant glioma therapeutics market segmented into chemotherapy, radiation therapy, targeted therapy, and others.
In terms of disease type, the market is studied for segments such as glioblastoma multiforme, anaplastic astrocytoma, anaplastic oligodendroglioma, and others. Various end-users covered under the report are hospitals, specialty clinics, cancer and radiation therapy centers, others. Geographically, the market is segmented into four major regions, which are North America, Europe, Asia Pacific, and the rest of the World. The regions are further categorized into countries.
To get information on various segments, share your queries with us
Along with this, the report provides elaborative analysis of the adult malignant glioma therapeutics market dynamics and competitive landscape. Various key insights provided in the report are the prevalence of glioma by key countries, an overview of technological advancements in the glioma therapy, recent industry developments such as mergers & acquisitions, and pipeline analysis.
By End User
As per our (Fortune Business Insights) study, the global adult malignant glioma therapeutics market is predicted to reach US$ 2,964.5 Mn by 2026 with a CAGR of 9.3% (2019 -2026).
Unmet medical needs, an increase in the global prevalence of the glioma disease, and growing affordability for advanced therapies such as targeted therapies are some of the key factors likely to drive the adult malignant glioma therapeutics market during the forecast period.
The radiation therapy segment is the leading segment in the adult malignant glioma therapeutics market by drug class.
North America is anticipated to hold the highest market share in the adult malignant glioma therapeutics market, and a high diagnosis rate owing to the growing awareness among the population about available therapy options are attributable to the high prevalence of malignant glioma and huge spending on healthcare.
Merck & Co., Inc. and F. Hoffmann-La Roche Ltd, Arbor Pharmaceuticals, Pfizer Inc., and AbbVie Inc are some of the leading players in the adult malignant glioma therapeutics industry.
In terms of disease type, the glioblastoma multiforme (GBM) segment held the largest market share in the adult malignant glioma therapeutics market in the year 2018.
Growing advancements in drug development have resulted in the successful applications of targeted therapies, which is likely to improve the survival rate in patients with glioblastoma multiforme, which is majorly attributable to targeted therapy segment to expand at the highest CAGR during the forecast period.